Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 107

recruiting
3 982
countries
28
conditions
2 106

3 662 trials match your criteria

Prostate cancer

Recruiting

Study on the Use of [18F]PSMA-1007 PET/CT Imaging for Detecting Prostate Cancer in Patients with Newly Diagnosed High-Risk or Very-High-Risk Conditions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:(2S)-2-[[(1S)-1-Carboxy-5-[[(2S)-2-[[4-[[[(2S)-4-Carboxy-2-[[(2S)-4-Carboxy-2-[(6-(18F)Fluoranylpyridine-3-Carbonyl)Amino]Butanoyl]Amino]Butanoyl]Amino]Methyl]Benzoyl]Amino]-3-Naphthalen-2-Ylpropanoyl]Amino]Pentyl]Carbamoylamino]Pentanedioic Acid

Acute myeloid leukaemia

Recruiting

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine

Crohn's disease

Recruiting

Study on Crohn's Disease: Evaluating Risankizumab's Effects in Children Aged 2 to 17 with Moderate to Severe Symptoms

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Risankizumab

Aortic stenosis

Recruiting

Study on Ticagrelor and Aspirin for Patients with Severe Aortic Stenosis After Heart Valve Replacement

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Major depression

Recruiting

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Agomelatine

Gastrooesophageal cancer+1

Recruiting

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel

ABO haemolytic disease of newborn

Recruiting

Study of Nipocalimab in Pregnant Women at Risk of Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Nipocalimab

Glycogen storage disease type II

Recruiting

Study on Gene Therapy with AAV9.LAMP2B for Male Patients with Danon Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Eculizumab

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa

Neonatal alloimmune thrombocytopenia

Recruiting

Study on Nipocalimab for Reducing Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-risk Pregnancies

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Nipocalimab

Crohn's disease

Recruiting

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab

Factor VIII deficiency+1

Recruiting

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Marstacimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.